Description
+ Include: 8 videos + 8 file sub vtt + 29 pdfs, size: 5.99 GB
+ Target Audience: cardiologists, internists, primary care physicians
+ Sample video: contact me for sample video
+ Information:
1. Overview
The Complete Conference Management 30th Annual Heart Failure 2026 program provides a highly specialized, comprehensive review of advanced heart failure management. The curriculum covers the latest innovations in pharmacotherapy, device therapy, genetic testing, and complex clinical scenarios—such as cardiogenic shock, myocarditis, and peripartum cardiomyopathy—equipping cardiovascular specialists to optimize patient outcomes across diverse etiologies.
Course Date: March 13 & 14, 2026
The 30th Annual Heart Failure 2026: An Update on Therapy continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure. The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide high level and clinically relevant updates on the contemporary approach for the prevention and management of acute and chronic heart failure with the goal of improving clinicians’ knowledge and the care of patients with heart failure of various etiologies.
Once again in 2026, the symposium will be a hybrid event – attend in-person at the Millennium Biltmore Hotel or online!
2. Learning Objectives
At the conclusion of this activity, participants should be able to:
- Provide comprehensive updates on the management of cardiovascular conditions, including new guidelines for hypertension, therapeutic options for hyperlipidemia, and contemporary approaches to heart failure with reduced and preserved ejection fraction.
- Review advanced treatment strategies for complex cardiovascular scenarios, including acute decompensated heart failure, heart failure with kidney disease, atrial fibrillation in heart failure patients, and catheter-based interventions for valvular heart disease.
- Discuss specialized management approaches for specific cardiovascular conditions, including heart failure due to hypertrophic cardiomyopathy and amyloidosis, obesity in heart failure patients, and pulmonary arterial hypertension.
3. Target Audience
Best for cardiologists, advanced heart failure specialists, and intensivists who want updates on GDMT, cardiogenic shock, and cardiomyopathy management.
The program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
4. Topics
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below
-
Case Discussions
-
Product Theatre Breakfast – Non-CME Navigating Fabry Disease
-
SESSION I
-
SESSION II
-
SESSION III
-
SESSION IV
-
SESSION V
-
SESSION VI
* Detail:
FRIDAY, March 13, 2026
- 11:00am-12:00pm Registration, Coffee, Visit Exhibits
- 12:00-1:00pm Product Theatre Luncheon – Non-CME Evidence – Based Treatment of Recurrent Pericarditis Mariko Harper, MD, MS, FACC Supported by: Kiniksa
- 1:00-1:15pm Coffee Break and Visit Exhibits
- SESSION I
- 1:15-1:25pm Introduction to the 30th Annual Symposium: Heart Failure 2026 – An Update on Therapy Uri Elkayam, MD, FACC
- 1:25-1:45pm Management of the Hospitalized Patients with Decompensated Heart Failure Uri Elkayam, MD, FACC
- 1:45-2:05pm Balancing GDMT and Hyperkalemia Ileana L. Piña, MD
- 2:05-2:25pm Digitoxin in Heart Failure: A Comeback for Digitalis? Tien Ng, PharmD
- 2:25-2:45pm Introducing Finerenone: A New Drug for the Management of Heart Failure and Chronic Kidney Disease Akshay Desai, MD
- 2:45-3:05pm Vericiguat in Heart Failure: When and How to Use It Barry Greenberg, MD
- 3:05-3:25pm The Contemporary Management of HFpEF Akshay Desai, MD
- 3:25-3:40pm Coffee Break and Visit Exhibits
- SESSION II
- 3:40-4:00pm Our Journey with Diuretics: 240 Years, and How Far Have We Come? Marvin Konstam, MD
- 4:00-4:20pm Treating Congestion in Patients with Acute Decompensated Heart Failure: Where Are We Now? Where Are We Going? William Abraham, MD
- 4:20-4:40pm Releasing the Brakes on the Immune System in Cancer: Implications in Myocarditis and Beyond Eric Yang, MD
- 4:40-5:00pm Clinical Experience with the Use of Myosin Inhibitors in the Treatment of Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy Jessica Wang, MD
- 5:00-5:20pm Contemporary Management of Obesity in Patients with Heart Failure Norman Lepor, MD
- 5:20pm Adjourn
SATURDAY, March 14, 2026
- 7:00am Registration Open
- 7:15-7:45am Case Discussion Uri Elkayam, MD and Barry Greenberg, MD
- 7:45-8:45am Product Theatre Breakfast – Non-CME Navigating Fabry Disease Dr. Anjay Rastogi Supported by: Sanofi
- 8:45-9:00am Break and Visit the Exhibits
- SESSION III
- 9:00-9:15am Introduction to Day Two: 30th Annual Symposium: Heart Failure 2026 – An Update on Therapy Uri Elkayam, MD
- 9:15-9:35am GDMT for Chronic HFrEF: How to Maximize the Benefits? Gregg Fonarow, MD
- 9:35-9:55am Cardiogenic Shock: Hemodynamic Classification and Management Rola Khedraki, MD
- 9:55-10:15am Percutaneous Coronary Interventions in Ischemic Cardiomyopathy – Does It Work? Christina Economides, MD
- 10:15-10:35am Bio-Omics in Heart Failure Diagnosis and Therapy Kirkwood Adams, MD
- 10:35-10:55am Break and Visit the Exhibits
- SESSION IV
- 10:55-11:15am Genetic Testing for Cardiomyopathy Josh Hare, MD
- 11:15-11:35am Gene Therapy for Patients with Cardiomyopathy Barry Greenberg, MD
- 11:35-11:55am Stem Cell Therapy for the Management of Myocardial Disease: A Status Report Josh Hare, MD
- 11:55-12:15pm Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy Uri Elkayam, MD
- 12:15-12:35pm Update on the Management of Atrial Fibrillation in Patients with Heart Failure Anil Bhandari, MD
- 12:35-1:35pm Product Theatre Luncheon – Non-CME Pivotal Trial and Cardiac Structure and Function Outcomes With CAMZYOS® in Patients With Symptomatic NYHA Class II-III Obstructive HCM Florian Rader, MD Supported by: Bristol Myers Squibb
- 1:35-1:50pm Break and Visit the Exhibits
- SESSION V
- 1:50-2:20pm KEYNOTE LECTURE 30 Years of Innovation in the Management of Heart Failure: A Perspective Clyde Yancy, MD
- 2:20-2:40pm Bromocriptine in the Management of Peripartum Cardiomyopathy: Pathophysiologic Mechanism and Available Data Uri Elkayam, MD
- 2:40-3:00pm What Is New in Myocarditis: An Update from the ESC 2025 Guidelines Leslie Cooper, MD
- 3:00-3:20pm Pulmonary Hypertension: New Drugs and How to Use Them Thomas Heywood, MD
- 3:20-3:40pm Innovations in Device Therapy for Heart Failure William Abraham, MD
- 3:40-4:00pm Break and Visit Exhibits
- SESSION VI
- 4:00-4:20pm The Use of AI in the Management of Heart Failure Nir Uriel, MD
- 4:20-4:40pm Autonomic Modulation in Heart Failure Treatment: Where Are We and Where Are We Heading? Marvin Konstam, MD
- 4:40-5:00pm LVAD vs Heart Transplantation: A Perspective Nir Uriel, MD
- 5:00-5:20pm Individual Selection of Drug Therapy in Patients with Transthyretin (TTR) Amyloidosis Mazen Hanna, MD
- 5:20pm Adjourn
Reviews
There are no reviews yet.